We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Study to Evaluate the Effect of Lansoprazole on Infants With Gastroesophageal Reflux Disease.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00220818
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : July 22, 2010
Information provided by:

September 9, 2005
September 22, 2005
July 22, 2010
January 2005
July 2005   (Final data collection date for primary outcome measure)
  • Pharmacokinetic Analysis. [ Time Frame: Day 1 and 5 ]
  • Mean Intragastric 24 hour pH (subset of 6 subjects) [ Time Frame: Day -1, 1 and 5 ]
Pharmacokinetic, pharmacodynamic and safety parameters.
Complete list of historical versions of study NCT00220818 on ClinicalTrials.gov Archive Site
Gastroesophageal Reflux Disease Symptom Assessment. [ Time Frame: Days 1-5 ]
Not Provided
Not Provided
Not Provided
A Study to Evaluate the Effect of Lansoprazole on Infants With Gastroesophageal Reflux Disease.
A Phase 1, Single- and Repeated-Dose, Randomized, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Lansoprazole in Infants With Clinically-Evident Gastroesophageal Reflux Disease.
The purpose of this study is to understand how quickly lansoprazole, once daily (QD), improves feeding in premature babies or babies less than 28 days of age.
A Phase 1, multicenter, pharmacokinetic/Pharmacodynamic and safety study in which infants will be randomized in an open-label fashion to receive 5 days of open-label treatment with lansoprazole pediatric suspension 1 mg/kg/day oral, or lansoprazole pediatric suspension 2 mg/kg/day oral. On Dosing Days 1 and 5, blood samples will be obtained for drug assay. All subjects will be evaluated for inclusion in the pH monitoring portion of the study and will undergo pH monitoring, provided it is clinically indicated, at the discretion of the investigator. Intragastric pH monitoring (up to 24 hours) will be performed at Baseline, on Dosing Day 1 (or Day 2) and on Dosing Day 5 (or Day 6). Intraesophageal pH may be done in addition to intragastric pH at the discretion of the investigator. Subjects will be evaluated for safety, including a follow-up visit on Post-Dosing Day 14.
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Gastroesophageal Reflux Disease
  • Drug: Lansoprazole
    Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
  • Drug: Lansoprazole
    Lansoprazole 2.0 mg/kg/day suspension, orally, once daily for up to 5 days.
  • Experimental: Lansoprazole 1.0 mg/kg QD
    Intervention: Drug: Lansoprazole
  • Experimental: Lansoprazole 2.0 mg/kg QD
    Intervention: Drug: Lansoprazole

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
July 2005
July 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Hospitalized or outpatient male or female, term or post-term infants beyond the neonatal period (>28 days) but less than 12 months of age, OR a preterm infant with a corrected age of at least 44 weeks but less than 12 months on Dosing Day 1.
  • Clinically-evident Gastroesophageal Reflux Disease (feeding intolerance, regurgitation, wheezing or stridor with feedings)
  • At least 7 days post-surgery without anticipated need for surgery during study
  • No significant laboratory abnormalities

Exclusion Criteria:

  • Unstable, clinically significant disease or abnormality
  • Congenital anomaly of the upper gastrointestinal tract
  • Clinical evidence of acute sepsis
  • Cystic fibrosis
  • Medical condition requiring subject to not be fed by mouth/gastric tube
Sexes Eligible for Study: All
up to 364 Days   (Child)
Contact information is only displayed when the study is recruiting subjects
Not Provided
U1111-1114-0294 ( Registry Identifier: WHO )
Not Provided
Not Provided
Sr. VP Clinical Sciences, Takeda Global Research & Development Center, Inc.
Not Provided
Study Director: Medical Director Takeda
July 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP